中国药业2025，Vol.34Issue(14)：24-28,5.DOI:10.3969/j.issn.1006-4931.2025.14.006
2021至2023年上海市崇明区国家医保谈判降糖药品可及性及应用分析
Analysis on the Accessibility and Application of Hypoglycemic Drugs in National Medical Insurance Negotiation in Chongming District of Shanghai from 2021 to 2023
摘要
Abstract
Objective To investigate the accessibility and application of hypoglycemic drugs in Chongming District of Shanghai from 2021 to 2023 in national medical insurance negotiation(referred to national negotiation).Methods The relevant data of hypoglycemic drugs in all medical institutions in Chongming District from 2021 to 2023 were collected.The availability rate,consumption sum,defined daily doses(DDDs)and their compound annual growth rate(CAGR)were calculated,and the defined daily dose cost(DDDc)and its decline rate before and after the implementation of the national negotiation were analyzed.Results From 2021 to 2023,there were 15 national negotiation hypoglycemic drugs with user records in Chongming District,of which 12 drugs were low availability,3 drugs were general,and the overall availability was low.Only 9 drugs could calculate the CAGR of availability rate,of which the CAGR of 3 drugs was-100%,2 drugs were 0,and 3 drugs were lower than 50%,one drug was higher than 100%,the CAGR of Insulin Degludec and Insulin Aspart Injection was the highest(134.53%).Only 9 drugs could calculate the CAGR of consumption sum,of which the CAGR of 3 drugs was-100%,1 drug was lower than 25%(17.77%),and 5 drugs were higher than 100%,the CAGR of Metformin Hydrochloride and Empagliflozin Tablets(Ⅰ)was the highest(445.73%).The CAGR of the total consumption sum of natioal negotiation hypoglycemic drugs,the total consumption sum of hypoglycemic drugs and the proportion of the two were 75.63%,2.32%and 71.62%,respectively.Only 9 drugs could calculate the CAGR of DDDs,of which the CAGR of 3 drugs was-100%,1 drug was lower than 25%(22.13%),and 5 drugs were higher than 100%,CAGR of Metformin Hydrochloride and Empagliflozin Tablets(Ⅰ)was the highest(445.24%).CAGR of DDDs of natioal negotiathon hypoglycemic drugs,DDDs of hypoglycemic drugs and the proportion of the two were 48.20%,9.27%and 35.76%,respectively.Compared with before the implementation of the national negotiation policy,the DDDc of each hypoglycemic drug was significantly reduced after the implementation of the national negotiation policy.Among them,the decrease of 6 drugs was more than 70%,with an average decrease of 64.73%,and the decrease of Ertugliflozin Tablets was the highest(91.35%).Conclusion The accessibility of hypoglycemic drugs in Chongming District is low.In the future,more national negotiation drugs should be included to improve the allocation rate.Additionally,in accordance with the national requirements for hierarchical diagnosis and treatment,efforts should be made to enhance medication coordination by extending more chronic disease medications to community health service centers,which will optimize the allocation of medical resources,improve the convenience of patient care,and alleviate their financial burden.关键词
国家医保谈判/降糖药品/药品可及性/药事管理Key words
national medical insurance negotiation/hypoglycemic drug/drug accessibility/pharmaceutical administration分类
医药卫生引用本文复制引用
范贇婷,王建新,施洲,倪寂..2021至2023年上海市崇明区国家医保谈判降糖药品可及性及应用分析[J].中国药业,2025,34(14):24-28,5.基金项目
上海市崇明区可持续发展科技创新行动计划项目[CKY2021-47]. （）
